Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. (Q46284853)

21 December 2017

title

Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. (English)

1 reference

21 December 2017

author name string

Peter J Smith

1

1 reference

21 December 2017

Jon A Olson

2

1 reference

21 December 2017

David Constable

3

1 reference

21 December 2017

Julie Schwartz

4

1 reference

21 December 2017

Richard T Proffitt

5

1 reference

21 December 2017

Jill P Adler-Moore

6

1 reference

21 December 2017

language of work or name

English

0 references

publication date

30 March 2007

1 reference

21 December 2017

Journal of Antimicrobial Chemotherapy

published in

1 reference

21 December 2017

volume

59

1 reference

21 December 2017

issue

5

1 reference

21 December 2017

page(s)

941-951

1 reference

21 December 2017

Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Impact of diagnostic markers on early antifungal therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

AmBisome (liposomal amphotericin B): a comparative review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Prevention of invasive fungal infections in liver transplant recipients: the role of prophylaxis with lipid formulations of amphotericin B in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Single-dose AmBisome (Liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Testing conditions for determination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparison of antifungal treatments for murine fusariosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rate model of pulmonary aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Liposome disposition in vivo. III. Dose and vesicle-size effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJAC%2FDKM077

21 January 2018

Identifiers

DOI

10.1093/JAC/DKM077

1 reference

21 December 2017

1 reference

21 December 2017